 Merck  Co and Endocyte Inc said Monday the companies have withdrawn conditional marketing authorization applications from the European Medicines Agency for an ovariancancer treatment The companies said the decision was based on further review of interim data from a clinical trial of vintafolide in combination with pegylated liposomal doxorubicin  Earlier
  